Experience gained with Durvalumab Maintenance Therapy after definitive Chemoradiotherapy in Patients with NSCLC: Survival- and Toxicity Data from Routine clinical Practice

Lettmaier S, Hecht M, Weissmann T, Fietkau R (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Strahlentherapie und Onkologie Urban & Vogel

Publisher: SPRINGER HEIDELBERG

City/Town: HEIDELBERG

Pages Range: S150-S150

Conference Proceedings Title: STRAHLENTHERAPIE UND ONKOLOGIE

Authors with CRIS profile

Markus Hecht Department of Radiation Oncology Thomas Weissmann Department of Radiation Oncology Rainer Fietkau Lehrstuhl für Strahlentherapie

How to cite

APA:

Lettmaier, S., Hecht, M., Weissmann, T., & Fietkau, R. (2021). Experience gained with Durvalumab Maintenance Therapy after definitive Chemoradiotherapy in Patients with NSCLC: Survival- and Toxicity Data from Routine clinical Practice. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S150-S150). HEIDELBERG: SPRINGER HEIDELBERG.

MLA:

Lettmaier, S., et al. "Experience gained with Durvalumab Maintenance Therapy after definitive Chemoradiotherapy in Patients with NSCLC: Survival- and Toxicity Data from Routine clinical Practice." Proceedings of the STRAHLENTHERAPIE UND ONKOLOGIE HEIDELBERG: SPRINGER HEIDELBERG, 2021. S150-S150.

BibTeX: Download